Sold as Trusopt. Every FDA application for this active ingredient: 1 branded and 14 generic.
As of Nov 15, 2026, FDA lists 15 applications for Dorzolamide Hydrochloride (sold as Trusopt), first approved Dec 9, 1994, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Dorzolamide HCl | Part D | $21.2M | -2% | 296,482 |
| Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECHPrimary Open-Angle Glaucoma (POAG), Ocular Hypertension · Tecnoquimicas | Phase 4 | Active, not recruiting | Jul 8, 2026 |
| Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle GlaucomaOcular Hypertension, Primary Open Angle Glaucoma · Ache Laboratorios Farmaceuticos S.A. | Phase 3 | Not yet recruiting | Jun 1, 2026 |
| Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma (POAG), Ocular Hypertension · Huons Co., Ltd. | Phase 3 | Recruiting | Jan 13, 2026 |
| Retinal Ganglion Cell Neuroprotection Under Prostaglandin AnaloguesGlaucoma · Association for Innovation and Biomedical Research on Light and Image | — | Not yet recruiting | Jul 20, 2025 |
| Efficacy of Simbrinza and Rocklatan vs Cosopt and LatanoprostOpen Angle Glaucoma · Prairie Eye Center | Phase 4 | Recruiting | Mar 19, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Hikma
Sandoz
Alembic